Vasopressin and its synthetic analog terlipressin are potent vasopressors that could be useful in vasodilatory septic shock. In septic adults, vasopressin/terlipressin have been shown to increase mean arterial pressure and to decrease the necessity for catecholamines. Moreover, low doses of vasopressin (or terlipressin) increase urine output and ameliorate oxygenation. Although pediatric septic shock is more often hypodynamic, both vasopressin and terlipressin have proved to be effective in restoring blood pressure or increasing the diuresis in this setting. The purpose of this review is to summarize the physiology of vasopressin and to report the available evidence for the use of vasopressin or terlipressin in pediatric septic shock in order to make best use in this population. We also report our experience with the continuous infusion ofterlipressin in two pediatric patients who developed catecholamine refractory septic shock.
Sepsis and septic shock are characterized by severe cardiocirculatory impairment that leads to profound hypotension. Relative hypovolemia (loss of intravascular volume from capillary leak and increased venous capacitance), myocardial dysfunction, and increased pulmonary vascular resistance are important contributors to the cardiocirculatory dysfunction (1) (2) .
Current treatments of septic shock include adequate volume replacement and vasopressive agents, most of them catecholamines (3) . However, in some patients these agents have proven to be ineffective in maintaining adequate blood pressure. This condition configures the clinical scenario of catecholamine refractory shock (I). Catecholamine refractory shock is a leading cause of death in septic patients, therefore an effective vasopressor therapy for severe hypotension is essential. Accumulating evidence suggests that low dose vasopressin (VP) is safe and effective for the treatment of vasodilatatory septic shock (4) . The rationale for its use is that a relative deficiency of VP often exists, the vascular responsiveness to VP seems to be intact during sepsis and also that synergy of action with adrenergic drugs may occur (4) (5) . In 1997, Landry and co-workers observed that VP plasma concentrations fell in septic patients and that the administration of low doses of VP restored blood pressure (4) . Based on these observations, the effects of exogenous VP in shock have become a goal for numerous investigations, and the effectiveness of VP and its analogues in raising blood pressure. has been largely confirmed (6) . Despite the evidence accumulated, the appreciation of this drug among pediatric intensivists in the setting of vasoplegic septic shock is not uniform, Synthetic VP (Pitressin®, Monarch Pharmaceuticals, Inc.) is not available in some countries, including Italy, where instead pharmacies have the synthetic analog lysine VP or terlipressin (TP) (Glypressine®, Ferring). The purpose of this review is to summarize the physiology ofVP in order to understand the rationale of its use in septic patients, and to report the available evidence for the use of VP/TP in pediatric septic shock. We also report personal experience with TP in two pediatric patients who developed catecholamine refractory septic shock.
Biology ofvasopressin Structure and synthesis ofvasopressin
Arginine VP, also known as antidiuretic hormone (ADH), is a nine aminoacid polypeptide hormone synthetized in the parvocellular and magnocellular neurones ofthe supraoptic and paraventricular nuclei of the hypothalamus as a larger precursor, and then is processed in a prohormone which is transported along the neuron axons to the posterior pituitary where it is secreted as final hormone. The whole process of VP synthesis, transport and storage in the posterior pituitary takes between one and two hours (7) (8) . As soon as VP reaches the posterior pituitary, 10 to 20% of the total VP store pool is released, while the subsequent secretion occurs in response to appropriate stimuli at a reduced rate and in a particular fashion (6) (7) . Specifically, the secretion diminishes as the stimulus continues, therefore the course of VP levels during septic shock is biphasic with an early elevation followed by subsequent diminution (7) (8) . VP is rapidly metabolized by the aminopeptidases that are present in most peripheral tissues. The half-life ofVP is 10-35 min. Vasopressin clearance depends on hepatic and renal blood flow. Normal VP concentrations are <4 pg/ml.
Regulation ofvasopressin secretion
VP has multiple physiologic effects. Its most well-known effects are suggested by its two names: "vasopressin" and "antidiuretic hormone". The regulation of secretion thus depends on blood pressure (or volemia) and serum osmolality.
Osmotic Regulation
Hyperosmolality is a potent stimulus for the release of VP (9-10). Plasma hypertonicity causes depolarization of the magnocellular neurones of the hypothalamus producing more VP release, whereas hypotonicity causes hyperpolarization which reduces VP release. In healthy adults, the osmotic threshold for VP secretion ranges from 275 to 290 mosmol/kg (average about 280 mosmol/kg). When plasma osmolality reaches about 290-292 mosmoll kg, plasma VP levels are about 5-6 pg/ml and urine concentration increases.
Hypotension/hypovolemia
Under normal resting conditions, afferent vagal impulses from the stretch receptors of the left atrium, aortic arch and carotid sinus inhibit VP secretion, while during hypotension (hypovolemia or decreased central venous pressure) baroreceptor activity stimulates the release of VP from the hypothalamus. Volume depletion produces little elevation in plasma VP levels until the blood volume decreases by more than 8-10%. However, further volume depletion results in exponential increases in plasma VP levels.
3. Other stimuli A variety of other stimuli, such as pain, nausea, hypoxia, hypercapnia, acidosis, pharyngeal stimuli, hypoglycemia, stress, temperature, cytokines, and endogenous or exogenous chemicals also increase release of VP (7) . These other stimuli often result in relatively inappropriate release of VP producing excess water retention and thus hyponatremia (SIADH) (11). Other non-osmotic stimuli include acetylcholine (via nicotinic receptors), dopamine, prostaglandins, angiotensin II, and catecholamines. Inhibitors of VP release include opioids, yaminobutyric acid, and atrial natriuretic peptide.
Mechanisms ofaction ofvasopressin
VP has two principle sites of action: the kidney and blood vessels. It acts through receptors: VI, V2, V3. VP receptors are G-protein coupled receptors with seven transmembrane spanning domains. The distribution and density of VP receptors are shown in Table I (8, 12) .
VI vascular receptors and the vasoconstrictor effect
V 1 receptors (previously known as V1 receptors) are located on vascular smooth muscle and mediate vasoconstriction. V l-receptor activation mediates vasoconstriction by receptor-coupled activation of phospholipase C and block of adenosine triphoshate channels allowing release of Ca'" from intracellular stores. Supraphysiologic plasma VP levels of about 50 pg/ml must be reached before a significant increase in mean arterial blood pressure is achieved. In addition to the blood vessels, VI receptors can also be found in the kidney, myometrium, bladder, adipocytes, hepatocytes, platelets, spleen, and testis. The vasoconstriction occurs predominantly in the small vessels of the skin skeletal muscle, small intestine and fat, but it causes less vasoconstriction in mesenteric, coronary, and cerebral circulations (13) (14) because of the NO-mediated vasodilating effect of VP on these circulations. During septic shock there is an increased sensitivity of V1 receptors (1, 6) , despite hypoxia and acidosis. Activation of VI receptors by high levels of VP may also lead to platelet aggregation (15).
2. V2 renal receptors V2 receptors are present in the renal collecting duct system and endothelial cells. Kidney V2 receptors interact with adenylyl cyclase to increase intracellular cyclic adenosine monophosphate (cAMP). This mobilizes aquaporin channels, which are inserted into the apical membrane of the renal collecting duct cells and endothelial cells. The V2 renal receptors are therefore responsible for the antidiuretic effects of VP by causing retention of water (16) (17) . In contrast with this antidiuretic effect, in patients with septic shock low-dose VP induces diuresis (18) (19) (20) . The diuretic effect of VP has not been fully elucidated. Possible mechanisms include downregulation of the V2 receptors, NO-mediated afferent arteriolar vasodilation and selective efferent arteriolar vasoconstriction which increases renal blood flow. It is not clear whether increased urine output is due to an improvement in renal function, as the creatinine does not change. Extra-renal V2 receptors appear to mediate the release of several coagulation factors (21) .
V3 pituitary receptors
Formerly known as Vlb receptors, they activate Gq protein and release intracellular Ca" after activation of phospholipase C and the phosphoinositol cascade. The V3 receptors are responsible for the actions of VP on the central nervous system, where they act as a neurotransmitter or a modulator controlling memory, blood pressure, body temperature and release of pituitary hormones, such as adrenocorticotropic hormone (ACTH) (22) . 4 
. Oxytocin receptors and the vasodilator effect
Vasopressin has equal affinity with oxytocin receptors and may exert its vasodilatory effects through this route. VP induced vasodilation is likely to be mediated by NO through endothelial oxytocin receptors which mobilize intracellular calcium (23) . The vasodilatory effects are primarily exerted on cerebral, renal and pulmonary circulation.
Terlipressin TP is a non-selective, synthetic analog of VP that has a slightly greater affinity for V1 receptors than VP (VIN2 receptor ratio of 2.2 versus 1 for VP) (24) . TP is a prodrug (triglycil-lysine VP) rapidly converted into lysine VP by endo and exo peptidases in the liver and in the kidney over 4-6 hours, thereby allowing prolonged effects (2-10 hours) by intermittent intravenous injections (8, 10) . TP may have some advantages over VP. It is less expensive and its long half-life (about 6 hours) makes single boluses possible, whereas VP must be given as an infusion (25) . However, bolus infusion may be limited due the potential adverse effects such as increased pulmonary vascular resistance and uncontrolled rise in blood pressure and, therefore, continuous infusion has been suggested (26) . The positive effects ofTP in septic shock have been shown in animal studies, clinical cases and observational studies.
Clinical evidence for the use of vasopressin/ terlipression in septic shock
Available studies on VP in the management of septic shock mostly consist of case series, while randomized controlled trials are few (Table II) (10) . On the basis of these studies, VP results effective in increasing mean blood pressure (without significant adverse effects on cardiac function or pulmonary hemodynamics), in decreasing the need for catecholamines and improving diuresis. In patients with refractory septic shock, VP should be used as a continuous low-dose infusion (between 0.01 and 0.04 U/min in adults) in conjunction with other agents and not titrated as a single vasopressor agent. The timing of VP administration is not yet clear.
Recently, a large clinical study on adults with septic shock demonstrated the beneficialeffects ofinitiating (27) . This makes sense, as earlier achievement of a normal hemodynamic status may improve outcome in septic shock and prevent end-organ damage.
There is great concern that VPITP could jeopardize splanchnic and pulmonary circulation in septic patients, because of its vasoconstrictive properties. Animal models of VP/TP treatment of septic shock have greatly contributed in clarifying this point. In particular, Asfar and co-workers showed that low dose TP (6 ug/kg) in fluid-challenged endotoxic rats significantly increased mean arterial pressure without decreasing aortic blood flow, an effect that was seen in non-fluid challenged endotoxic rats where TP induced detrimental effects both on splanchnic macrocirculation and microcirculation (24) .
Terlipressinlvasopressin in pediatric septic shock
The use of VP or TP for hyperdynamic vasodilatory septic shock is appealing. However, differently from septic adults, most children in septic shock have low cardiac function and high systemic vascular resistance (hypodynamic septic shock). In this setting, a vasoconstrictor may further hamper myocardial function and decrease tissue perfusion. In addition, children in septic shock often change hemodynamic profiles. For example, vasodilatory shock may subsequently change to hypodynamic shock (28) . In this respect, a long-acting vasopressor as TP seems hazardous. In addition, the metabolism of children, especially newborns, is different from that of adults and so the clearance of VP could be different. Also, the concept of low-dose VP "hormonal replacement" therapy for catecholamineresistant vasodilatory shock may not be correct in septic infants where it is not clear if the VP levels are consistently low (29) (30) . Finally, in children as well as in adults there is no evidence, at present, that the hemodynamic benefits improve outcome.
The data on the efficacy and safety of TPNP in septic shock in pediatrics are scanty. However, they are consistent with those in adult patients with septic shock: TP can increase the mean arterial pressure and decrease catecholamine requirements.
Clinical experience with VPITP in children with septic shock
Several studies have been published at the time of this review. In all of them, TP or VP have been used as compassionate therapy and in a small number of patients. In some studies TP has been used as intermittent boluses while in others as continuous infusion due to the concern about the consequences ofsevere vasoconstriction and ischaemia. Rodriguez-Nunez and co-workers studied four patients with severe septic shock and profound hypotension despite volume replacement and elevated doses of norepinephrine or other catecholamines (31) . TP was used at a dose of 20 ug/kg every 4 h for a minimum of 48 h and max 72 h. In all patients TP induced a rapid and sustained improvement in mean arterial pressure, which allowed the reduction, or even withdrawal, of norepinephrine infusion. No adverse effects were noted. The same authors subsequently reported the results of a survey carried out in nine pediatric intensive care units in Spain. TP was administered as a bolus (20 ug/kg) every four hours in sixteen pediatric patients with refractory septic shock. Similarly to their previous results, TP produced an increase in mean arterial pressure which allowed a reduction in catecholamine infusion (32) . More recently, the same authors published the case of a 2-month-old infant who presented with septic shock, refractory to high doses of catecholamines. Continuous infusion of TP (10 ug/kg/h) produced a rapidly significant increase in the mean arterial pressure, so allowing a reduction in the rate of catecholamine infusion; however, 18 h later the baby failed to respond to therapy and died (26) . Several other studies have confirmed these results. Peters published a case report of an l l-yr-old male with gram negative shock and low vascular resistance (33) . TP (14 ug/kg as a bolus) rapidly increased his systemic vascular resistances, thereby allowing rapid weaning of the norepinephrine infusion. Matok et al. reported on a newborn who had nosocomial sepsis with Klebsiella (34) . Administration ofTPatadose of? ug/kg every 12 hours for 50 hours was given. An improvement of respiratory, metabolic and neurologic status was observed following this treatment. In a subsequent study, Matok et al. retrospectively reviewed the results of the use of TP in 14 children with septic shock (35) . Significant improvement in respiratory and hemodynamic indices was noted shortly after treatment. In particular, urine output increased from 1.6 ± 0.5 mllkglh to 4.3 ± 1.2 mllkg/h I h after onset of treatment (p=O.Oll). Vasudevan described VP infusion for catecholamine-refractory septic shock in three children in whom hypotension and poor perfusion persisted despite use of multiple infusions of vasopressors and inotropes (36) . All three had a rapid improvement in hypotension and perfusion after starting VP infusion, allowing tapering of other infusions. Two children recovered completely.
Efrati evaluated the effect of VP administration on hemodynamic and ventilatory parameters in critically ill children (37) . Eight children (I month to 12 years old) with severe septic shock or cardiogenic shock were treated with VP continuously at a dose of 0.0003-0.002 U/kg/min. Systolic and diastolic blood pressure increased significantly following VP initiation, while the epinephrine requirement decreased. Oxygenation index and PaO/Fi0 2 ratio improved significantly, and ventilatory support requirement and positive inspiratory pressure (PIP) significantly decreased. The efficacy of VP (0.035-0.36 U/kglh) was also assessed in extremely low birth weight infants with acute renal injury due to septic or non-septic shock. In the infants with septic shock systemic blood pressure increased substantively with restoration of urine output. The mortality rate was 1/3 (38) .
Side effects ofvasopressin
Ischemic lesions have been estimated to occur in 10 to 30% ofpatients receiving low-dose VP infusions (39) . Severe skin necrosis after extravasation has been reported and peripheral administration of low-dose VP infusions should be discouraged. High-dose VP administration has been associated with hypertension, bradycardia, arrhythmias, and myocardial infarction, especially in patients with cardiovascular disease. Other adverse reactions such as toxic rhabdomyolysis, hypersensitivity reactions, metabolic acidosis or ischaemic colitis, have been described in isolated cases; however, they must be considered when treating a patient in shock.
Personal experience
Case report n.I . A 3-year-old boy was admitted to his local hospital because of high fever, leg pain and purpuric skin lesions which led to the suspicion of meningococcal sepsis. Ceftriaxone was immediately administered and because of progressive loss of consciousness, mechanical ventilation was instituted. On admission to our PICU, the child presented severe shock, high fever resistant to antipyretics, and massive skin necrosis. Blood pressure was undetectable using a Dinamap BP monitor. Arterial blood gases showed hypoxia with severe metabolic acidosis: pH 6.88, PC0 2 56 mmHg, P0 2 36 mmHg, bicarbonate 10 mmollL, and base excess of -21. Blood tests showed: WBC 3900; platelet count 12.000; prothrombin time (PT)-INR 2.07 and the partial thromboplastin time (PTT)-ratio of3.14. Neisseria meningitides was then isolated from the blood culture. Fluids (cristalloids, colloids and plasma) were given up to 200 cc/kg and infusions of dobutamine and norepinephrine (0.2 ug/kg/min) were started. Despite aggressive fluid replacement the boy soon developed oliguric renal insufficiency associated with massive rabdomyolysis and myoglobinuria (myoglobin plasma levels 52, 899 ng/ml). Several hours later, the child become hypotensive (42/20mmHg) and p02 decreased despite Fi0 2 of 1 and a pC0 2 in the normal range. After informed parental consent, TP (10 ug/kg as a bolus) was administered. A few minutes later a significant increase in the mean blood pressure was observed as well as in pa0 2. After a few hours, the blood pressure started to decrease so continuous intravenous infusion was commenced at a rate of 10 ug/kg/h, TP was given for 20 hours; during this time the mean blood pressure ranged between 70 and 80 mmHg despite a reduction in norepinephrine infusion. After two days of this treatment, levosimendan was added to his treatment regimen because of the evidence of ongoing cold shock, and norepinephrine was gradually withdrawn.
His respiratory and circulatory conditions improved during the following days, whereas renal insufficiency persisted, and hemodyalisis was continued until day 12 after admission when he died because of poor neurologic status.
Case n.2 P.P. was born at 40 weeks' gestation to a mother who had a history of fever for a few days prior to delivery. The infant was born by spontaneous vaginal delivery with Apgar scores of 7 at 1 and 9 at 5 minutes. The amniotic fluid was meconium stained. After 20 hours the baby developed fever, poor feeding and worsening respiratory distress because of which he was transferred at 30 hours of life to our pediatric intensive care unit. On arrival his condition was critical, he was started on high frequency oscillatory ventilation and nitric oxide because of intractable hypoxemia. Arterial blood gases showed hypoxia with severe mixed acidosis: pH 6.93, PCO z 110 mmHg, PO z 40 mmHg, bicarbonate 14 mmol/L, and base excess of -9. Blood tests showed: WBC 1410; platelet count 48,000; prothrombin time (PT)-INR 3.17 and the partial thromboplastin time (PTT)ratio of 2.58. Blood cultures showed the presence of Listeria monocytogenes. The baby was given fluids (30 cc/kg) including plasma, and dopamine was started (10 ug/kg/min). His oxygenation improved but after a few hours he developed oliguria «0.5 cc/kg/h) and severe hypotension (50/25 mmHg) despite the increase of dopamine to 20 mcglkg/min and the addition of norepinephrine (1.5 ug/kg/min). His cardiac function was within normal ranges and his extremities were warm. The baby also presented a worsening in oxygenation. A bolus of 10 ug/kg of TP was given without response. A continuous infusion was then started at a dose of 10 ug/kg/h and increased to 20 ug/kg/h, After TP infusion which was continued for 9 hours, blood pressure returned in the normal range and FiO z requirement and urine output increased. Catecholamine requirement was reduced. After this initial clinical improvement the baby worsened again. TP was recommenced at 20 ug/kg/h with no improvement and he finally died at 6 days old.
CONCLUSIONS
The available evidence on the use of TPNP to sustain blood pressure in catecholamine-resistant septic shock is encouraging, however there is not enough information to favor VP or TP to other vasoactive agents as first line-therapy. In adults, as well as in children, low doses ofVP and TP not only restore blood pressure but also increase urine output in oliguric renal insufficiency that is associated with septic shock. Furthermore, VP seems to improve oxygenation. Adverse effects mostly include skin necrosis after extravasation and ischemia of the gastrointestinal tract when fluids are not adequately administered. Based on current knowledge, the suggestion is that VP or TP therapy should be started at low doses only if an appropriate fluid challenge plus catecholamine infusion fail to restore an adequate arterial blood pressure.
